Dr. Usmani on Impact of BCMA on the Myeloma Treatment Landscape

Video
Conference|International Myeloma Society Annual Meeting

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how the target BCMA is impacting the multiple myeloma treatment landscape.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how the target BCMA is impacting the multiple myeloma treatment landscape.

<<< 17th International Myeloma Workshop

Related Videos
Muhamed Baljevic, MD
Sundar Jagannath, MBBS
Sundar Jagannath, MBBS
James Ignatz-Hoover, MD, PhD
Sundar Jagannath, MBBS
Elias Jabbour, MD
Joseph G. Jurcic, MD
Krina K. Patel, MD, MSc
Minoo Battiwalla, MD
Angela Jia, MD, PhD, of University Hospitals
Related Content
Carlos Barrios, MD

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

May 17th 2024
Article
Paul G. Richardson, MD

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023
Podcast
Sibylle Loibl, MD, PhD, chair, German Breast Group, chief executive officer, GBG Forschungs GmbH

Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer

May 17th 2024
Article
Ajay K. Nooka, MD, MPH, FACP

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023
Podcast
T-DXd in HER2+ Metastatic Breast Cancer | Image Credit: © Axel Kock - stock.adobe.com

T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer

May 16th 2024
Article
Mafalda Oliveira, MD, PhD

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

May 16th 2024
Article